Last updated: May 28, 2026
Mexiletine hydrochloride supply is typically split across (1) API manufacturers and (2) branded and generic finished-dose suppliers. The key supply question for R&D, contracting, and litigation planning is whether you can source mexiletine HCl at the API level under appropriate quality systems, and whether finished products have tied regulatory filings (e.g., ANDA) that constrain substitution.
Who supplies mexiletine hydrochloride API and what are the main sourcing channels?
Mexiletine hydrochloride is generally supplied through two commercial routes:
- Active pharmaceutical ingredient (API) manufacturers producing mexiletine HCl (and sometimes producing upstream intermediates that are then converted to the salt form).
- Finished-dose manufacturers supplying capsules or tablets that source the API from one or more qualified vendors.
In practice, API procurement for a small-molecule such as mexiletine HCl often consolidates into a limited set of qualified suppliers due to:
- assay and impurity control requirements for basic amines,
- salt-formation robustness (conversion to HCl salt),
- stability and polymorph/particle-size consistency constraints for oral solid dosage forms.
What do buyers typically request in mexiletine hydrochloride API sourcing packages?
Common supplier deliverables include:
- CoA with assay and impurity profile,
- DMF reference information or CEP documentation (where applicable),
- validation package support for solid oral manufacturing,
- nitrosamine and solvent residue controls aligned with current quality expectations for small-molecule APIs.
Which finished-dose formats are most commonly supplied for mexiletine?
Commercial mexiletine products are typically supplied as oral capsules or tablets. Supply commitments are usually tied to:
- dosage strength,
- manufacturing site qualification,
- batch release history,
- and the regulatory listing under the applicable FDA NDA/ANDA.
Which companies sell mexiletine hydrochloride finished capsules or tablets in the US?
Finished-dose availability depends on whether the product is under a branded NDA or a generic ANDA. Buyers should map:
- which label holders currently sell mexiletine HCl in the US,
- which ANDAs cover the dosage forms,
- and which manufacturers are responsible for specific NDCs.
What is the Orange Book status of mexiletine hydrochloride and what does it imply for sourcing?
Orange Book entries drive substitution risk and contracting strategy. Where patents or exclusivity remain, sourcing may be limited to label and contract manufacturing partners tied to the listed products. Where exclusivity has expired, multiple generic suppliers can compete, increasing price leverage for procurement.
What patents or exclusivity affect mexiletine hydrochloride supply or generic entry?
Supply constraints can come from patent and regulatory exclusivity as much as from manufacturing capacity.
Does mexiletine hydrochloride face supply constraints from US exclusivity or patent listings?
If a listed drug’s exclusivity/patents remain in force, generic manufacturers may face:
- Paragraph IV certification barriers,
- settlement-driven “launch date” restrictions,
- or design-around requirements for formulation or method-of-use claims (less common for basic immediate-release solids, but still possible via impurity, particle size, or polymorph-related claims).
What does this mean for contract manufacturing and API procurement?
- If the market is dominated by a small number of finished-dose products with limited entrants, procurement may be routed through those label holders.
- If multiple ANDAs exist for mexiletine HCl, buyers can qualify alternative manufacturers for supply continuity.
What is the strongest way to identify mexiletine hydrochloride suppliers for procurement: DMF, CEP, or FDA filings?
For mexiletine HCl, the most audit-ready sourcing mapping typically uses layered evidence:
- API-level evidence
- DMF holder name and the referenced manufacturing site(s)
- CEP/EDMF if available
- Finished-dose regulatory evidence
- ANDA/NDA application number(s)
- manufacturer names shown for drug product manufacturing and packaging
- Quality evidence
- CoA patterns for assay and impurity profile
- variability in particle size or physical form if supplied as a salt
How do you qualify mexiletine hydrochloride suppliers for US oral solid manufacturing?
Qualification is driven by:
- impurity controls (process-related impurities),
- salt-formation and residual HCl criteria,
- polymorph/physical form monitoring,
- and stability under shipping and storage conditions.
What manufacturing barriers are common for mexiletine HCl APIs?
Common constraints include:
- securing control of amine-containing intermediates,
- reproducible salt formation and drying parameters,
- and scaling a synthetic route while preserving impurity control.
Which intermediates and upstream feedstocks matter for mexiletine hydrochloride API suppliers?
API supply resilience depends on intermediates and key reagents used in mexiletine HCl synthesis. In procurement due diligence, buyers typically map:
- whether an API supplier also supplies key intermediates,
- lead times for critical reagents,
- and whether the supplier can support change notifications for process changes that might affect impurity profiles.
What generic entry risks exist for mexiletine hydrochloride, and how do they affect supplier selection?
Generic entry risk is mostly regulatory and legal:
- if a generic’s ANDA requires a specific impurity profile or relies on a particular manufacturing process,
- or if there are method-of-use or formulation patents that affect labeling or bioequivalence strategy.
Where supply is concentrated, buyers can also face:
- single-site dependency risk for finished-dose manufacturing.
Key takeaways
- Mexiletine hydrochloride supply is typically sourced through a limited number of API manufacturers plus label holders for finished-dose tablets/capsules.
- Procurement-quality mapping should be evidence-based using DMF/CEP data for API and FDA NDA/ANDA listings for finished-dose suppliers.
- Patent and exclusivity status can constrain the number of eligible finished-dose suppliers even when API capacity exists.
- Qualification for oral solid manufacturing hinges on impurity control, salt formation reproducibility, and physical form/stability consistency.
FAQs
1) How do I find mexiletine hydrochloride API DMF holders?
Use FDA DMF listings tied to the relevant API references for mexiletine HCl used in marketed oral solid products.
2) Which FDA filings list the drug product manufacturer for mexiletine hydrochloride generics?
ANDA labeling and application information identifies the drug product manufacturing and packaging details that tie to specific NDCs.
3) What quality tests matter most for mexiletine hydrochloride API salts?
Assay, specified impurity profile, residual solvents, water content, and salt formation related controls.
4) Can mexiletine hydrochloride supply be disrupted by contract manufacturing constraints?
Yes, finished-dose manufacturing site concentration can create bottlenecks independent of API availability.
5) What’s the fastest way to validate a new mexiletine hydrochloride supplier?
Qualification package review anchored on CoA consistency, impurity profile compatibility, and evidence of regulatory-grade manufacturing documentation.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. Drug Master Files (DMF) database and associated regulatory submissions.
